97871-02-8

Upstream product

• 99248-22-3 benzyl (S)-3-tert-butoxycarbonylamino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-5-acetate 
• 1493-27-2 ortho-nitrofluorobenzene 
• 99197-78-1 (S)-2-((tert-butoxycarbonyl)amino)-3-(2-nitrophenoxy)propanoic acid 
• 99197-79-2 2(S)-3-(2-aminophenoxy)-2-((tert-butoxycarbonyl)amino)propanoic acid 
• 99197-80-5 (S)-tert-butyl (4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine-3-yl)aminoformate 
• 140-18-1 Benzyl chloroacetate 

Downstream Products

• 99198-00-2 benzyl 3(S)-ethoxycarbonylmethylamino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-5-acetate 
• 197902-87-7 (7-{2-[(benzyloxy-formyl-amino)-methyl]-3-phenyl-propionylamino}-8-oxo-7,8-dihydro-6H-5-oxa-9-aza-benzocyclohepten-9-yl)-acetic acid benzyl ester 
• 99198-23-9 benzyl 3(S)-[1(R)-ethoxycarbonyl-5-phthalimidopentyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-5-acetate 
• 97871-11-9 benzyl 3(S)-[1(R)-ethoxycarbonyl-3-cyclohexylpropyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-5-acetate 
• 99198-62-6 benzyl 3(S)-[5-(1-benzyloxycarbonyl-4-piperidyl)-1(R)-ethoxycarbonylpentyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-5-acetate 
• 99198-56-8 benzyl 3(S)-[4-(1-benzyloxycarbonyl-4-piperidyl)-1(R)-ethoxycarbonylbutyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-5-acetate 
• 208717-68-4 benzyl 2-[(3S)-3-(isoquinolin-1-oyl)amino-4-oxo-2,3,4,5-tetrahydro-5H-1,5-benzoxazepin-5-yl]-ethanoate 

Relevant academic research and scientific papers

N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors

N-formyl hydroxylamines are provided which have the structure wherein R is H, alkyl, alkenyl, aryl-(CH2)p—, heteroaryl-(CH2)p— or cycloheteroalkyl-(CH2)p— R1is H or COR2where R2is alkyl, aryl-(CH2)p—, cycloheteroalkyl-(CH2)p—, heteroaryl-(CH2)p—, alkoxy or cycloalkyl-(CH2)p—, p is 0 to 8, and A is a dipeptide derived from an amino acid or is a conformationally restricted dipeptide mimic. The above compounds are useful in treating hypertension congestive heart failure, renal failure, and hepatic cirrhosis.

3-Amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives

Novel 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives of the formula STR1 [wherein R1 and R2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R3 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl; R4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted cycloalkylalkyl; Y is a carboxyl group which may be esterified or amidated; m is 1 or 2] and salts thereof. These compounds and salts thereof exhibits inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases (e.g. hypertension, cardiopathy, cerebral apoploxy).